Impact of Pharmaceutical Industry R&D Trends on CRO Contract Business
First written in FY2019. 3 of 5 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「Domestic pharmaceutical companies face a more challenging business environment due to drug price revisions and the spread of generic drugs, and have tended to restrain R&D spending in recent years.」
The company has reconfirmed the risk that pharmaceutical companies' restraint on R&D spending and changes in the environment may affect contracts in the drug discovery support business. - FY2021RestatedAnnual report
「The drug discovery support business derives a high proportion of its revenue from outsourced nonclinical and clinical studies for pharmaceutical companies and has maintained relatively stable orders. Meanwhile, domestic pharmaceutical companies face a more challenging business environment due to drug price revisions and the spread of generic drugs, and have tended to restrain R&D spending in recent years.」
The company has reconfirmed the risk that pharmaceutical companies' restraint on R&D spending and changes in the business environment may affect contracts in the drug discovery support business. - FY2020RestatedAnnual report
「The CRO business derives a high proportion of its revenue from outsourced nonclinical and clinical studies for pharmaceutical companies and has maintained relatively stable orders. Meanwhile, domestic pharmaceutical companies face a more challenging business environment due to drug price revisions and the spread of generic drugs, and have tended to restrain R&D spending in recent years.」
The company has reconfirmed the risk that pharmaceutical companies' restraint on R&D spending and changes in the business environment may affect CRO contracts. - FY2020-Q3MaterialisedAnnual report
「However, orders from major pharmaceutical companies remained sluggish, and CRO business orders for the first 3 quarters of the current fiscal year totaled ¥1,524.096 million, up 0.9% year on year, remaining at approximately the previous fiscal year's level.」
The risk that pharmaceutical companies' R&D trends may affect CRO contracts has materialized in the business in the form of sluggish orders from major pharmaceutical companies. - FY2019First statedAnnual report
「The CRO business derives a high proportion of its revenue from outsourced nonclinical and clinical studies for pharmaceutical companies and may therefore be significantly affected by trends in pharmaceutical industry R&D activity.」
The company has newly identified the risk that pharmaceutical industry R&D trends may affect performance, given the high proportion of CRO revenue generated by outsourced nonclinical and clinical studies for pharmaceutical companies.